Dexcom Inc Stock Cash And Equivalents
| DC4 Stock | EUR 71.30 1.02 1.45% |
DexCom Inc fundamentals help investors to digest information that contributes to DexCom's financial success or failures. It also enables traders to predict the movement of DexCom Stock. The fundamental analysis module provides a way to measure DexCom's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DexCom stock.
DexCom |
DexCom Inc Company Cash And Equivalents Analysis
DexCom's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current DexCom Cash And Equivalents | 1.38 B |
Most of DexCom's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DexCom Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, DexCom Inc has 1.38 B in Cash And Equivalents. This is 68.11% higher than that of the Healthcare sector and 222.17% higher than that of the Diagnostics & Research industry. The cash and equivalents for all Germany stocks is 48.93% higher than that of the company.
DexCom Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DexCom's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DexCom could also be used in its relative valuation, which is a method of valuing DexCom by comparing valuation metrics of similar companies.DexCom is rated # 4 in cash and equivalents category among its peers.
DexCom Fundamentals
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0474 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 42.38 B | |||
| Shares Outstanding | 386.41 M | |||
| Shares Owned By Insiders | 0.42 % | |||
| Shares Owned By Institutions | 99.58 % | |||
| Price To Earning | 191.84 X | |||
| Price To Book | 24.95 X | |||
| Price To Sales | 15.73 X | |||
| Revenue | 2.91 B | |||
| Gross Profit | 1.88 B | |||
| EBITDA | 565.3 M | |||
| Net Income | 341.2 M | |||
| Cash And Equivalents | 1.38 B | |||
| Cash Per Share | 15.11 X | |||
| Total Debt | 1.2 B | |||
| Debt To Equity | 159.90 % | |||
| Current Ratio | 6.05 X | |||
| Book Value Per Share | 5.52 X | |||
| Cash Flow From Operations | 669.5 M | |||
| Earnings Per Share | 0.75 X | |||
| Price To Earnings To Growth | 11.47 X | |||
| Target Price | 530.6 | |||
| Number Of Employees | 7.5 K | |||
| Beta | 1.11 | |||
| Market Capitalization | 40.57 B | |||
| Total Asset | 5.39 B | |||
| Z Score | 19.8 | |||
| Net Asset | 5.39 B |
About DexCom Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DexCom Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DexCom using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DexCom Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in DexCom Stock
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.